COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma15/10/2025
-   
  Le plus grand rassemblement de médecins de famille au pays posera ses valises à Winnipeg en novembre15/10/2025
-   
  Canada’s Largest Family Medicine Gathering Comes to Winnipeg This November15/10/2025
-   
  Communiqué de presse : Sanofi fait de Montpellier le coeur mondial de la recherche translationnelle sur les maladies auto-immunes15/10/2025
-   
  Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting15/10/2025
-   
  Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital15/10/2025
-   
  Amphista Therapeutics nominates AMX-883, an orally available Targeted Glue™ degrader of BRD9, as its first clinical development candidate for the treatment of acute myeloid leukaemia15/10/2025
-   
  Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 202515/10/2025
-   
  Transpire Bio Granted Orphan Drug Designation by the U.S. FDA For Two Rare Diseases15/10/2025
-   
  Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis15/10/2025
-   
  Algernon Pharmaceuticals Completes Name Change to Algernon Health15/10/2025
-   
  Bexorg Raises $42.5M to Transform CNS Drug Development with World’s First Integrated AI and Whole-Human Brain Platform15/10/2025
-   
  Verano Announces Grand Opening of Zen Leaf Antwerp in 19th Century Historic Ohio Train Depot, Offering Cannabis Consumers One of the Most Unique Dispensary Shopping Experiences in the U.S.15/10/2025
-   
  Fortrea Announces Date for Third Quarter 2025 Financial Results and Conference Call15/10/2025
-   
  Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers15/10/2025
-   
  SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio15/10/2025
-   
  60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study15/10/2025
-   
  Repligen to Report Third Quarter 2025 Financial Results15/10/2025
-   
  Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome15/10/2025
Pages